Millennium Management LLC Sells 133,208 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Millennium Management LLC decreased its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 39.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 207,778 shares of the biotechnology company's stock after selling 133,208 shares during the quarter. Millennium Management LLC owned approximately 0.24% of Anavex Life Sciences worth $2,232,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Deutsche Bank AG boosted its holdings in Anavex Life Sciences by 63.3% in the fourth quarter. Deutsche Bank AG now owns 64,544 shares of the biotechnology company's stock worth $693,000 after purchasing an additional 25,024 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in shares of Anavex Life Sciences in the fourth quarter worth about $1,129,000. Cetera Investment Advisers bought a new stake in shares of Anavex Life Sciences during the 4th quarter worth about $150,000. Ameriprise Financial Inc. boosted its stake in shares of Anavex Life Sciences by 5.1% during the 4th quarter. Ameriprise Financial Inc. now owns 66,810 shares of the biotechnology company's stock worth $718,000 after acquiring an additional 3,243 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Anavex Life Sciences by 1.6% during the 4th quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company's stock valued at $7,592,000 after acquiring an additional 10,938 shares during the last quarter. Institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Trading Up 3.7%

AVXL traded up $0.28 during trading on Tuesday, hitting $7.84. The stock had a trading volume of 1,783,806 shares, compared to its average volume of 1,218,277. The firm has a market cap of $669.32 million, a PE ratio of -14.25 and a beta of 0.82. Anavex Life Sciences Corp. has a 12 month low of $3.51 and a 12 month high of $14.44. The company has a 50 day simple moving average of $8.49 and a 200-day simple moving average of $9.09.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. During the same period in the prior year, the business earned ($0.13) earnings per share. As a group, sell-side analysts anticipate that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Monday, April 7th. D. Boral Capital reissued a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.